Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00212693

Enrollment

165

Registered

2005-09-21

Start date

2004-01-31

Completion date

Unknown

Last updated

2012-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

ONO-2506PO, Parkinson's disease

Brief summary

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Interventions

DRUGONO-2506PO

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to 79 Years

Healthy volunteers

Inclusion criteria

1. Diagnosis of Parkinson's disease 2. Stage 2 - Stage 4 of revised Hoehn & Yahr severity score 3. Taking L-dopa/DCI without changing dose and regimen 4. Having motor complication 5. Other inclusion criteria as specified in the study protocol

Exclusion criteria

1. Previous participation in ONO-2506PO or ONO-2506 protocol 2. Previous brain surgery for Parkinson's disease 3. Presence or history of serious cardiac disease 4. Other

Design outcomes

Primary

Measure	Time frame
Unified Parkinson's disease rating scale (Part III)	—

Secondary

Measure	Time frame
Unified Parkinson's disease rating scale (Part I, II, IV and total), revised Hoehn & Yahr severity score and off time	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026